The role of cyclosporin in prolonging survival in vascularized bone allografts

James P. Paskert, Michael J. Yaremchuk, Mark A. Randolph, Andrew J. Weiland

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


It is known that experimental vascularized bone allo-grafts are subject to host rejection. To be useful clinically, this rejection response would need to be controlled. Cyclosporin is a potent immunosuppressant whose precise role in vascularized bone allograft transplantation has not been established. Using a proven reliable vascularized knee allograft model in inbred rats, cyclosporin was used postoperatively both continuously and short term (14 days after transplant) at 10 mg/kg per day as recipient treatment. Across a strong histocompatibility barrier, continuous cyclosporin was required for long-term graft survival. Short-term therapy delayed rejection for 4 to 6 weeks. However, across a weak histocompatibility barrier, short-term therapy was as effective as continuous therapy in achieving long-term graft survival. The implication is that a limited course of cyclosporin may be clinically successful in sustaining vascularized bone allograft survival, provided the genetic disparity between graft and host has been minimized by genetic matching techniques.

Original languageEnglish (US)
Pages (from-to)240-247
Number of pages8
JournalPlastic and reconstructive surgery
Issue number2
StatePublished - Aug 1987

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'The role of cyclosporin in prolonging survival in vascularized bone allografts'. Together they form a unique fingerprint.

Cite this